Add to ORKGCASE SUMMARY: A 79-year-old man with prostate cancer previously treated in 1997 with radical prostatectomy and subsequently treated with hormone therapy (ADT, abiraterone), chemotherapy (docetaxel, cabazitaxel), and strontium for metastatic bone disease presented in July 2017 with rising PSA levels. The patient’s PSA levels rose from 764 ug/L on July 4, 2017, to 1,722 ug/L on Sept. 5, 2017, 1,950 ug/L on Sept. 25, 2017, to 2,481 ug/L on Nov.1, 2017, when gallium-68 ( 68Ga) PSMA-11 PET/CT scanning was performed
Prostate specific membrane antigen (PSMA) is expressed in unfavorable prostate cancer. PSMA is basis...
Introduction: Prostatic carcinoma has variable course of disease progression. Patients with metasta...
Prostate cancer is the most frequent genitourinary tumor worldwide. Maintaining an optimum bone heal...
A 60-year-old man visited the previous hospital with difficulty of urination in July 2004. Serum pro...
A 70-year-old man is referred to a urologist for recommendations on the management of metastatic pro...
A 67-year old man was diagnosed with advanced prostate cancer with multiple pelvic lymph nodes and m...
Bone metastases alone or in combination with androgen deprivation therapy-related bone loss places p...
A 68-year-old man presented with gross hematuria. A papillary urethral tumor adjacent to the verumon...
Today prostatic adenocarcinoma is the most commonly di-agnosed malignancy in men. Organ confined tum...
A 42-year-old man visited a community hospital with chief complaints of lumbago and dyschesia. Compu...
<p>Prostate specific membrane antigen, a type II transmembrane protein is an excellent target for th...
In recent years, studies have been reported about the combination of androgen deprivation therapy (A...
DergiPark: 541685tmsjAims: Prostate cancer is one of the most prevalent cancers worldwide and someti...
Background: In case of oligo-recurrent prostate cancer (PC) following prostatectomy, 68Ga-PSMA-PET/C...
Purpose: The early and accurate diagnosis of locoregional recurrence or metastasis in prostate cance...
Prostate specific membrane antigen (PSMA) is expressed in unfavorable prostate cancer. PSMA is basis...
Introduction: Prostatic carcinoma has variable course of disease progression. Patients with metasta...
Prostate cancer is the most frequent genitourinary tumor worldwide. Maintaining an optimum bone heal...
A 60-year-old man visited the previous hospital with difficulty of urination in July 2004. Serum pro...
A 70-year-old man is referred to a urologist for recommendations on the management of metastatic pro...
A 67-year old man was diagnosed with advanced prostate cancer with multiple pelvic lymph nodes and m...
Bone metastases alone or in combination with androgen deprivation therapy-related bone loss places p...
A 68-year-old man presented with gross hematuria. A papillary urethral tumor adjacent to the verumon...
Today prostatic adenocarcinoma is the most commonly di-agnosed malignancy in men. Organ confined tum...
A 42-year-old man visited a community hospital with chief complaints of lumbago and dyschesia. Compu...
<p>Prostate specific membrane antigen, a type II transmembrane protein is an excellent target for th...
In recent years, studies have been reported about the combination of androgen deprivation therapy (A...
DergiPark: 541685tmsjAims: Prostate cancer is one of the most prevalent cancers worldwide and someti...
Background: In case of oligo-recurrent prostate cancer (PC) following prostatectomy, 68Ga-PSMA-PET/C...
Purpose: The early and accurate diagnosis of locoregional recurrence or metastasis in prostate cance...
Prostate specific membrane antigen (PSMA) is expressed in unfavorable prostate cancer. PSMA is basis...
Introduction: Prostatic carcinoma has variable course of disease progression. Patients with metasta...
Prostate cancer is the most frequent genitourinary tumor worldwide. Maintaining an optimum bone heal...